

**RECEIVED**  
**CENTRAL FAX CENTER****SEP 01 2005****FAX TRANSMISSION** **Matter # 10104199****DATE:** September 1, 2005**PTO IDENTIFIER:** Application Number 09/900,766  
Patent Number**Inventor:** Göran Forsberg et al.**MESSAGE TO:** US Patent and Trademark Office  
Patent Examiner: Patricia Duffy (Art Unit: 1645)**Phone Number:** (571-272-0855**FAX NUMBER:** (571) 273-8300**FROM:** FULBRIGHT & JAWORSKI L.L.P.

David L. Fox (09998)

**PHONE:** (713) 651-8231**Attorney Dkt. #:** HO-P02188US0**PAGES (including Cover Sheet):** 16**CONTENTS:** Supplemental Amendment in Response to Non-Final Office Action (10 pages)  
Declaration under 37 CFR 1.132 (4 pages)  
Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (713) 651-8231 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

**FULBRIGHT & JAWORSKI L.L.P.**  
Fulbright Tower, 1301 McKinney, Suite 5100, Houston, Texas 77010-3095  
Telephone: (713) 651-5151 Facsimile: (713) 651-5246

**RECEIVED  
CENTRAL FAX CENTER**

**SEP 01 2005**

Docket No.: HO-P02188US0  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Goran Forsberg et al.

Application No.: 09/900,766

Confirmation No.: 7699

Filed: July 6, 2001

Art Unit: 1645

For: NOVEL ENGINEERED SUPERANTIGEN FOR  
HUMAN THERAPY

Examiner: P. A. Duffy

**SUPPLEMENTAL AMENDMENT IN RESPONSE TO NON-FINAL OFFICE  
ACTION**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTORY COMMENTS**

In response to the Office Action dated January 5, 2005, please amend the above-identified U.S. patent application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.

25570896.1